Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy (Q38082845)

28 August 2017

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy (English)

1 reference

28 August 2017

1 reference

Omid Hamid

1

1 reference

PubMed ID

23421934

28 August 2017

Richard D Carvajal

series ordinal

2

1 reference

PubMed ID

23421934

28 August 2017

language of work or name

English

0 references

publication date

19 February 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

6

1 reference

28 August 2017

847-861

1 reference

Cancer immunotherapy: the past, the present and the future

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Immunotherapy of cancer in 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Interferons in the treatment of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-1 inhibits antiviral immunity at the effector phase in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

A molecular perspective of CTLA-4 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Modulation of tryptophan catabolism by regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Cutting edge: IFN-gamma enables APC to promote memory Th17 and abate Th1 cell development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Dual biological effects of the cytokines interleukin-10 and interferon-γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Differential binding properties of B7-H1 and B7-DC to programmed death-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Immunotherapy earns its spot in the ranks of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4+ T cells in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.770836

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.8525

Identifiers

DOI

10.1517/14712598.2013.770836

1 reference

28 August 2017

1 reference

PubMed ID

23421934